Athira Pharma, INC Form 4 insider transactions
Javier San Martin, Chief Medical Officer of Athira Pharma, reports acquisition and disposal of company stock related to RSU vesting and tax obligations.
Athira Pharma's CEO, Mark Litton, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.
Kevin Church, Chief Scientific Officer of Athira Pharma, reports stock acquisitions and disposals, including ESPP purchases and sales to cover tax obligations.
Robert Renninger, VP of Finance at Athira Pharma, reports stock acquisitions and disposals, including ESPP purchases, RSU vesting, and sales to cover tax obligations.
Athira Pharma's General Counsel and CCO, Mark Worthington, reports multiple transactions involving the company's stock, including acquisitions through an employee stock purchase plan and vesting of restricted stock units.
Mark Litton, CEO of Athira Pharma, files an amended SEC Form 4 to correct the exercise price of a stock option granted on October 3, 2024.
Robert Renninger, VP of Finance at Athira Pharma, reports acquisition of shares through stock options and restricted stock units.
Javier San Martin, Chief Medical Officer of Athira Pharma, acquired 140,000 stock options and 140,000 restricted stock units on October 1, 2024, according to a recent SEC filing.
Kevin Church, Chief Scientific Officer of Athira Pharma, acquired 110,000 Restricted Stock Units and 110,000 stock options on October 1, 2024, according to a recent SEC filing.
Mark Worthington, General Counsel and CCO of Athira Pharma, received 110,000 stock options and 110,000 restricted stock units on October 1, 2024.
Athira Pharma's CEO, Mark Litton, was granted 325,000 restricted stock units and 325,000 stock options on October 3, 2024, according to a Form 4 filing.
Andrew Gengos, CFO of Athira Pharma, reports acquisition and disposal of company stock related to RSU vesting and ESPP purchase.
Form 4: Athira Pharma COO Rachel Lenington Reports Stock Transactions Following Clinical Trial Results
Athira Pharma's COO, Rachel Lenington, reports acquisition of 10,000 shares from vested restricted stock units and subsequent sale of 2,525 shares to cover tax obligations after the public readout of the LIFT-AD Phase 2/3 clinical trial results.
Kevin Church, Chief Scientific Officer of Athira Pharma, reports acquisition and disposal of company stock related to ESPP purchases and RSU vesting, including sales to cover tax obligations.
Mark Worthington, General Counsel of Athira Pharma, reports acquisition and disposal of company stock related to RSU vesting and ESPP purchases.
Athira Pharma's CEO, Mark Litton, reports the vesting of restricted stock units (RSUs) and subsequent sale of shares to cover tax obligations following the public readout of the LIFT-AD Phase 2/3 clinical trial results.
Director Kelly A. Romano recently purchased additional shares of Athira Pharma, Inc. common stock, increasing their holdings.
Director Kelly A. Romano acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024, according to a Form 4 filing.
Director Joseph Edelman acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024.
Director James A. Johnson acquired stock options in Athira Pharma, Inc. on May 24, 2024.
Director Barbara Kosacz acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024.
Director Michael A. Panzara acquired stock options in Athira Pharma, Inc. on May 24, 2024.
Director Grant Pickering acquired 20,900 stock options in Athira Pharma, Inc. on May 24, 2024, according to a Form 4 filing.
Director John M. Fluke Jr. of Athira Pharma, Inc. acquired stock options on May 24, 2024, as reported in a Form 4 filing with the SEC.
Javier San Martin, Chief Medical Officer of Athira Pharma, acquired 400,000 stock options on April 15, 2024, according to a recent SEC filing.